1Cell.Ai, a leader in precision oncology diagnostics, is proud to announce the presentation of seven research studies at the ๐ผ๐ข๐๐ง๐๐๐๐ฃ ๐ผ๐จ๐จ๐ค๐๐๐๐ฉ๐๐ค๐ฃ ๐๐ค๐ง ๐พ๐๐ฃ๐๐๐ง ๐๐๐จ๐๐๐ง๐๐ (AACR) Annual Meeting 2026. These studies collectively demonstrate the power of AI-powered multi-omic approaches in advancing cancer detection, monitoring, and treatment decision-making.
“Our presence at AACR this year marks a pivotal moment for 1Cell.Ai,” said Mohan Uttarwar, Founder and CEO of 1Cell.Ai.
Key highlights from the presentations were categorized across ๐๐ค๐ช๐ง critical areas of oncology:
- ๐ผ๐๐ซ๐๐ฃ๐๐๐ข๐๐ฃ๐ฉ๐จ ๐๐ฃ ๐๐๐ฃ๐๐ข๐๐ก ๐๐๐จ๐๐๐ช๐๐ก ๐ฟ๐๐จ๐๐๐จ๐ (๐๐๐ฟ) & ๐๐๐ฆ๐ช๐๐ ๐ฝ๐๐ค๐ฅ๐จ๐ฎ: Novel computational and assay-based approaches to improve detection sensitivity.
โข MIRAGE: A ctDNA methylation-driven algorithm for sensitive MRD detection.
โข Ultrasensitive cfDNA fragmentomics assay for early treatment response assessment in solid tumors.
- ๐ผ๐-๐ฟ๐ง๐๐ซ๐๐ฃ ๐๐ข๐๐๐๐ฃ๐ & ๐ฝ๐๐ค๐ข๐๐ง๐ ๐๐ง ๐๐ช๐๐ฃ๐ฉ๐๐๐๐๐๐ฉ๐๐ค๐ฃ: Leveraging deep learning to extract deeper biological insights from standard pathology.
โข OncoPredikt: A deep-learning framework for tumor detection and biomarker quantification in breast cancer IHC whole-slide images.
- ๐๐ฃ๐ฉ๐๐๐ง๐๐ฉ๐๐ ๐๐ช๐ก๐ฉ๐-๐๐ข๐๐ & ๐๐๐๐ง๐ข๐๐๐ค๐๐๐ฃ๐ค๐ข๐๐ ๐๐ง๐ค๐๐๐ก๐๐ฃ๐: Combining diverse data types to enable more precise and actionable clinical insights.
โข Integrative genomic analysis revealing pharmacogenomic determinants of chemotherapy response.
โข Enhancing variant interpretation and reducing uncertainty in clinical genomics through systematic multi-database classification.
- ๐๐๐๐ก-๐๐ค๐ง๐ก๐ ๐๐ซ๐๐๐๐ฃ๐๐ & ๐๐ค๐ฅ๐ช๐ก๐๐ฉ๐๐ค๐ฃ-๐๐ฅ๐๐๐๐๐๐ ๐ผ๐ฅ๐ฅ๐ก๐๐๐๐ฉ๐๐ค๐ฃ๐จ: Expanding the reach of precision medicine to diverse cohorts and complex mutations.
โข Comprehensive genomic profiling expanding accessibility to targeted therapies in underserved populations.
โข Precision profiling of TP53alterations in advanced cancers, linking mutation class to genomic instability and actionable drivers.
“๐ฟ๐ง. ๐๐ค๐ฌ๐๐๐ง, Chief Medical Informatics Officer, added: ‘The diversity of these studies from fragmentomics to population-specific genomic profiling, highlights the scalability of our informatics platform. By integrating multi-omic insights, we are reducing clinical uncertainty and providing a clearer path forward for patients with complex high-risk mutations.'”
The full details of these presentations and their implications for the future of oncology care are available here.